Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Javier Villanueva-Meyer, MD
Headshot of Javier Villanueva-Meyer
Javier Villanueva-Meyer

Description

Summary

This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior

Official Title

Pilot/Phase I Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Details

Keywords

Meningioma, Hyperpolarized carbon C 13 pyruvate, Magnetic Resonance Image (MRI), Saline, Hyperpolarized 13C pyruvate, Magnetic Resonance Imaging

Eligibility

Location

  • UCSF accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Javier Villanueva-Meyer, MD
    Javier Villanueva­-Meyer, MD, is an Associate Professor in the Neuroradiology section in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He received his medical degree from Baylor College of Medicine in Houston, Texas, and he completed his one-year internship at Virginia Tech Carilion School of Medicine in Roanoke.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Javier Villaneuva-Meyer, MD
ID
NCT06014905
Phase
Phase 1 Meningioma Research Study
Study Type
Interventional
Participants
Expecting 50 study participants
Last Updated